Center-Authored Papers

Filters: Author is Lara, Primo N  [Clear All Filters]
2008
Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley J, Gandara DR.  2008.  Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(3):463-7. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract
2009
Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford DE.  2009.  Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.. The Journal of urology. 181(2):512-6;discussion516-7. Abstract
Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR.  2009.  Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(1):87-92. Abstract
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK et al..  2009.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3540-6. Abstract
deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MHA, Crawford DE.  2009.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).. The Journal of urology. 181(6):2476-80;discussion2480-1. Abstract
Le Q-TX, Moon J, Redman MW, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley J, Moore DF, Gandara DR.  2009.  Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(18):3014-9. Abstract
Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler PJ, Dakhil SR et al..  2009.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2530-5. Abstract
2012
Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW.  2012.  Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity.. Clinical lung cancer.
2013
Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk PJ et al..  2013.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.. The lancet oncology. 14(9):893-900. Abstract
2014
Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ et al..  2014.  Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.. Journal of the National Cancer Institute. Abstract
Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC.  2014.  Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications.. Clinical lung cancer. 15(1) Abstract
2015
Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR.  2015.  SWOG S0709: Randomized Phase II Trial of Erlotinib Versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR.  2015.  Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(1):110-5. Abstract
Lara PN, Gandara DR, Redman MW.  2015.  Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(5):e36.
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR.  2015.  Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.. Clinical lung cancer. Abstract
2017
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS et al..  2017.  Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.. Clinical genitourinary cancer. Abstract